Relay Therapeutics Inc (NASDAQ:RLAY)’s traded shares stood at 1.04 million during the last session, with the company’s beta value hitting 1.61. At the close of trading, the stock’s price was $4.51, to imply a decrease of -5.85% or -$0.28 in intraday trading. The RLAY share’s 52-week high remains $11.16, putting it -147.45% down since that peak but still an impressive 22.39% since price per share fell to its 52-week low of $3.50. The company has a valuation of $754.89M, with an average of 1.72 million shares in intraday trading volume over the past 10 days and average of 2.39 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Relay Therapeutics Inc (RLAY), translating to a mean rating of 1.23. Of 8 analyst(s) looking at the stock, 0 analyst(s) give RLAY a Sell rating. 1 of those analysts rate the stock as Overweight while 2 advise Hold as 5 recommend it as a Buy.
Relay Therapeutics Inc (NASDAQ:RLAY) trade information
After registering a -5.85% downside in the last session, Relay Therapeutics Inc (RLAY) has traded red over the past five days. The 5-day price performance for the stock is -0.66%, and -1.31% over 30 days. With these gigs, the year-to-date price performance is 9.47%. Short interest in Relay Therapeutics Inc (NASDAQ:RLAY) saw shorts transact 15.21 million shares and set a 5.71 days time to cover.
The extremes give us $16 and $20 for target low and target high price respectively. As such, RLAY has been trading -343.46% off suggested target high and -254.77% from its likely low.
Relay Therapeutics Inc (RLAY) estimates and forecasts
Looking at statistics comparing Relay Therapeutics Inc share performance against respective industry, we note that the company has underperformed competitors. Relay Therapeutics Inc (RLAY) shares are -37.27% down over the last 6 months, with its year-to-date growth rate lower than industry average at 8.60% against 17.90%.
An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -38.74% for the past 5-year period. While 2025 is set for a 9.80% return in earnings, projections for the next 5 years are at 2.87% annually.
RLAY Dividends
Relay Therapeutics Inc has its next earnings report out in March. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Relay Therapeutics Inc (NASDAQ:RLAY)’s Major holders
Relay Therapeutics Inc insiders hold 1.82% of total outstanding shares, with institutional holders owning 98.93% of the shares at 100.77% float percentage. In total, 98.93% institutions holds shares in the company, led by SB INVESTMENT ADVISERS (UK) LTD. As of 2024-06-30, the company held over 27.9 million shares (or 21.0093% of shares), all amounting to roughly $181.94 million.
The next major institution holding the largest number of shares is VANGUARD GROUP INC with 11.7 million shares, or about 8.8125% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $76.32 million.
